西罗珠单抗
| 单克隆抗体 | |
|---|---|
| 种类 | 完整抗体 |
| 目标 | 成纤维细胞激活蛋白 |
| 临床资料 | |
| ATC码 |
|
| 识别信息 | |
| CAS号 | 216669-97-5  |
| ChemSpider |
|
| UNII | |
西罗珠单抗（INN：sibrotuzumab）是一种用于治疗癌症的人源化单克隆抗体。它与成纤维细胞激活蛋白结合。[1][2]
2003年，它在转移性结直肠癌的II期临床试验中失败。[3]
参考资料
- ^ Scott AM, Wiseman G, Welt S, Adjei A, Lee FT, Hopkins W, et al. A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer. Clinical Cancer Research. May 2003, 9 (5): 1639–47. PMID 12738716.
- ^ Kloft C, Graefe EU, Tanswell P, Scott AM, Hofheinz R, Amelsberg A, Karlsson MO. Population pharmacokinetics of sibrotuzumab, a novel therapeutic monoclonal antibody, in cancer patients. Investigational New Drugs. January 2004, 22 (1): 39–52. PMID 14707493. S2CID 24877721. doi:10.1023/B:DRUG.0000006173.72210.1c.
- ^ Hofheinz RD, al-Batran SE, Hartmann F, Hartung G, Jäger D, Renner C, et al. Stromal antigen targeting by a humanised monoclonal antibody: an early phase II trial of sibrotuzumab in patients with metastatic colorectal cancer. Onkologie. February 2003, 26 (1): 44–8. PMID 12624517. S2CID 29922209. doi:10.1159/000069863.